Equities researchers at Stifel Nicolaus initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) in a note issued to investors on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $86.00 price target on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 278.85% from the stock’s previous close.
A number of other brokerages have also recently commented on JSPR. TD Cowen initiated coverage on shares of Jasper Therapeutics in a research report on Monday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th. Oppenheimer reiterated an “outperform” rating and issued a $80.00 target price on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Finally, Evercore ISI assumed coverage on shares of Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price target on the stock. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $67.00.
View Our Latest Analysis on Jasper Therapeutics
Jasper Therapeutics Stock Performance
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last issued its earnings results on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.23. On average, analysts predict that Jasper Therapeutics will post -4.36 earnings per share for the current year.
Institutional Investors Weigh In On Jasper Therapeutics
A number of large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $306,000. Ikarian Capital LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,088,000. StemPoint Capital LP bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Russell Investments Group Ltd. bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $2,343,000. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $599,000. Institutional investors own 79.85% of the company’s stock.
About Jasper Therapeutics
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Featured Stories
- Five stocks we like better than Jasper Therapeutics
- Stock Average Calculator
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Short Selling: How to Short a Stock
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.